To The Moon

$ARM Holdings Ltd(ARM)$ We are all full of hope, dreams and proper DD.r/wallstreetbets - We are all full of hope, dreams and proper DD.

Tomorrow Daddy Powell ready to deliver,That would be a violent turn of events. $DJIA(.DJI)$ $S&P 500(.SPX)$ $SPDR S&P 500 ETF Trust(SPY)$ r/wallstreetbets - Tomorrow Daddy Powell ready to deliver

I noticed a message on Weibo that a top fund manager on Wall Street warned that Morgan Stanley's short position in gold derivatives may exceed the bank's total assets. First, I am not sure about the authenticity of this news. Second, I believe that this news is not entirely groundless, as there must be a reason behind the rumor. Third, in my opinion, some financial institutions on Wall Street are being pressured by high-level government officials to suppress the price of gold. Otherwise, with the amount of gold purchased by various countries last year, gold would have already reached a historical high. Fourth, if this news is accurate, there is a high possibility that Morgan Stanley will be surrounded by other major players in the world, and gold may skyrocket. Fifth, even if this informat

The FAANG era is apparently over. The U.S. market is dominated by just two stocks now.$Apple(AAPL)$ $Microsoft(MSFT)$ The combined weighting ofAppleInc.AAPL-0.91%decrease; red down pointing triangleandMicrosoftCorp.MSFT-0.54%decrease; red down pointing trianglein the S&P 500 has risen to 13.3%, the highest level on record, while the influence of other big technology stocks has waned of late. That is according to Strategas Securities data going back to 1990.Not sinceInternational Business MachinesCorp.IBM-1.99%decrease; red down pointing triangleandAT&Tin 1978 have two stocks made up a greater share of the benchmark, according to Howard Silverblatt, senior index analyst at S&P Dow Jones Indices

Kala Pharmaceuticals , Inc .KALA announced that the FDA has accepted its investigational new drug (IND) application for its lead product candidate, KPI-012, which is being developed for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing.The company plans to begin a phase IIb study evaluating KPI-012 for treating PCED in the first quarter of 2023.The randomized, vehicle-controlled, parallel-group phase IIb study will enroll around 90 adult patients with PCED and is designed to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution versus vehicle for 56 days. The primary endpoint of the study will check the complete healing of the PCED as measured by corneal fluorescein staining.Top-line data from the above-mentioned